• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Novo Nordisk, Sempre Health Launch Pilot to Improve Medication Costs for Diabetic Patients

by Jasmine Pennic 04/19/2018 Leave a Comment

sempre health_novo nordisk

Sempre Health, a solution for behavior-based healthcare pricing has announced a pilot program with Novo Nordisk to add diabetes medications to the Sempre Health’s affordability & engagement solution. Unlike traditional coupons and vouchers, Sempre works with health plans to reward their membership’s positive choices and actions. For example, a patient may earn a lower copay if she fills her prescription on time. The two companies are seeking to engage 10,000 patients with diabetes on the Sempre Health platform in 2018.

Taking medication as prescribed, particularly diabetes medication, is tied to better clinical outcomes and reduced healthcare costs. Sempre has created an innovative solution for behavior-based healthcare pricing. They work with health plans and pharma to reward their membership’s positive choices and actions, seamlessly at the point of fill. Similar to a “good driver discount” with car insurance, if a patient is adherent and takes her medications regularly, she will pay less when filling her prescriptions. 

“This is the first of several innovations we plan to pilot to help reduce how much patients pay for their diabetes medicines at the pharmacy. And because consistently taking medicines is important for blood sugar control, we’re keen to see Sempre Health’s adherence approach support patients,” said Steve Albers, Corporate Vice President, Market Access and Public Affairs, Novo Nordisk Inc.

In November 2016, Novo Nordisk made a commitment to finding solutions involving pricing stability and affordability. This partnership with Novo Nordisk builds off a previous health plan partnership announced in 2017.

Tagged With: Diabetes Management, Novo Nordisk, Sempre Health

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |